Literature DB >> 19858735

Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model.

Isaac George1, Steve Xydas, Stefan Klotz, Ilan Hay, Chuck Ng, Jonathan Chang, Kai Xu, Zhihe Li, Andrew A Protter, Ed X Wu, Mehmet C Oz, Jie Wang.   

Abstract

INTRODUCTION: The effects of exogenous B-type natriuretic peptide (BNP) on postmyocardial infarction (MI) are not known. We tested the hypothesis that in vivo infusion of BNP would improve cardiac function and affect left ventricular (LV) remodeling in an experimental model of MI.
METHODS: MI was induced by coronary ligation in rats and confirmed by echocardiography. 19 rats were randomized to 1 of 3 groups: sham (n = 7), MI + saline (n = 5), MI + BNP (400 ng.kg(-1).minute(-1)) (n = 7). Infusions were delivered for 7 days via venous catheters tunneled to an infusion pump. Rats were followed for 8 weeks. Echocardiography, hemodynamics, histology, and in vivo and ex vivo pressure-volume relationships were examined.
RESULTS: LV systolic pressure, LV dP/dtmax, and infarct size improved with BNP treatment versus control MI group (132 +/- 4 vs.110 +/- 2 mm Hg, 8097 +/- 317 vs. 5816 +/- 378 mm Hg/s, 19.3% +/- 1.6% vs. 23.3% +/- 1.9%, respectively; all P < 0.05). Ex vivo end-diastolic pressure-volume relationship demonstrated reduced diastolic dysfunction after BNP therapy (P < 0.05 vs. control MI). Serum BNP levels confirmed delivery of BNP.
CONCLUSIONS: We demonstrate beneficial effects on LV function and decreased LV remodeling with BNP infusion in an experimental model of acute MI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19858735      PMCID: PMC3085010          DOI: 10.1097/FJC.0b013e3181c5e743

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  26 in total

1.  Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.

Authors:  F Zijlstra; A Patel; M Jones; C L Grines; S Ellis; E Garcia; L Grinfeld; R J Gibbons; E E Ribeiro; F Ribichini; C Granger; F Akhras; W D Weaver; R J Simes
Journal:  Eur Heart J       Date:  2002-04       Impact factor: 29.983

2.  Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs.

Authors:  Kun-Lun He; Geng-Hua Yi; Warren Sherman; Hua Zhou; Ge-Ping Zhang; Anguo Gu; Race Kao; Howard B Haimes; John Harvey; Eric Roos; Desmond White; Doris A Taylor; Jie Wang; Daniel Burkhoff
Journal:  J Heart Lung Transplant       Date:  2005-08-24       Impact factor: 10.247

3.  Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases.

Authors:  Toshihiro Tsuruda; Guido Boerrigter; Brenda K Huntley; Josh A Noser; Alessandro Cataliotti; Lisa C Costello-Boerrigter; Horng H Chen; John C Burnett
Journal:  Circ Res       Date:  2002-12-13       Impact factor: 17.367

4.  Cardiac fibrosis in mice lacking brain natriuretic peptide.

Authors:  N Tamura; Y Ogawa; H Chusho; K Nakamura; K Nakao; M Suda; M Kasahara; R Hashimoto; G Katsuura; M Mukoyama; H Itoh; Y Saito; I Tanaka; H Otani; M Katsuki
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

5.  Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction.

Authors:  M Hayashi; T Tsutamoto; A Wada; K Maeda; N Mabuchi; T Tsutsui; H Horie; M Ohnishi; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  2001-06-01       Impact factor: 24.094

6.  beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy.

Authors:  Steve Xydas; Aftab R Kherani; Jonathan S Chang; Stefan Klotz; Ilan Hay; Christopher J Mutrie; Garrett W Moss; Anguo Gu; Allison R Schulman; Daqing Gao; Debora Hu; Ed X Wu; Chiming Wei; Mehmet C Oz; Jie Wang
Journal:  J Pharmacol Exp Ther       Date:  2006-01-18       Impact factor: 4.030

7.  Subcutaneous administration of brain natriuretic peptide in experimental heart failure.

Authors:  H H Chen; J A Grantham; J A Schirger; M Jougasaki; M M Redfield; J C Burnett
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

8.  Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.

Authors:  Yuhao Li; Ichiro Kishimoto; Yoshihiko Saito; Masaki Harada; Koichiro Kuwahara; Takehiko Izumi; Nobuki Takahashi; Rika Kawakami; Keiji Tanimoto; Yasuaki Nakagawa; Michio Nakanishi; Yuichiro Adachi; David L Garbers; Akiyoshi Fukamizu; Kazuwa Nakao
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

9.  B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening.

Authors:  Savio P D'Souza; Derek M Yellon; Claus Martin; Rainer Schulz; Gerd Heusch; Annamaria Onody; Peter Ferdinandy; Gary F Baxter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-01-09       Impact factor: 4.733

10.  Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study.

Authors:  Philip Jong; Erika Vowinckel; Peter P Liu; Yanyan Gong; Jack V Tu
Journal:  Arch Intern Med       Date:  2002 Aug 12-26
View more
  2 in total

1.  Do engineered natriuretic peptides have greater therapeutic potential than do native peptides?

Authors:  Arthur H L From
Journal:  Cardiovasc Res       Date:  2010-10-08       Impact factor: 10.787

2.  A Novel Collagen Matricryptin Reduces Left Ventricular Dilation Post-Myocardial Infarction by Promoting Scar Formation and Angiogenesis.

Authors:  Merry L Lindsey; Rugmani Padmanabhan Iyer; Rogelio Zamilpa; Andriy Yabluchanskiy; Kristine Y DeLeon-Pennell; Michael E Hall; Abdullah Kaplan; Fouad A Zouein; Dustin Bratton; Elizabeth R Flynn; Presley L Cannon; Yuan Tian; Yu-Fang Jin; Richard A Lange; Dorota Tokmina-Roszyk; Gregg B Fields; Lisandra E de Castro Brás
Journal:  J Am Coll Cardiol       Date:  2015-09-22       Impact factor: 24.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.